Eli Lilly

FDA approves new Alzheimer’s drug that slows memory decline – National

by
FDA approves new Alzheimer’s drug that slows memory decline – National

The U.S. Food and Drug Administration on Tuesday approved Eli Lilly’s treatment for early Alzheimer’s, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients. The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency’s outside experts, who … Read more

Decision on Eli Lilly’s Alzheimer’s drug delayed by U.S. FDA – National

by
Decision on Eli Lilly’s Alzheimer’s drug delayed by U.S. FDA – National

The U.S. Food and Drug Administration has delayed its decision on Eli Lilly’s LLY.N experimental treatment for early Alzheimer’s disease and will hold a meeting of outside experts to discuss its safety and efficacy, the company said. The FDA’s decision came as a surprise to company officials and many Alzheimer’s experts, who had expected a … Read more